Feature|Articles|March 13, 2024
- Pharmaceutical Executive: March 2024
- Volume 44
- Issue 3
Pharmaceutical Executive: March 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
How’s Business?almost 2 years ago
Eyeing Efficiency for Allalmost 2 years ago
Positioning Medical Information as a Trust Driver for Your Brandalmost 2 years ago
Straight and Simple Advice Lives On in the Pharma Industryalmost 2 years ago
A Return to the Fundamentals in Biotech Investment?about 2 years ago
The Shifting Landscape of the Life Sciences Job Marketabout 2 years ago
Copay Adjustment Programs: What’s Next for Manufacturers?Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Vinay Prasad Out at CBER for Second Time in Under a Year
2
Key Factors Contributing to Uncertainty in Moderna's mRNA Vaccine Review
3
Ipsen Withdraws Tazverik from Market Due to Emerging Data from Clinical Trial
4
Mergers and Acquisitions Roundup: GSK and Alfasigma Enter Licensing Agreement for Linerixibat, Servier Enters $2.5 Billion Definitive Agreement to Acquire Day One Pharmaceuticals
5